Literature DB >> 7149305

The anesthetic potency of fentanyl in terms of its reduction of enflurane MAC.

M R Murphy, C C Hug.   

Abstract

Infusion rates for fentanyl were calculated to produce stable plasma concentrations at which the ability of fentanyl to reduce enflurane MAC could be studied utilizing the tail clamp method and measurement of end-tidal enflurane. Following the determination of control enflurane MAC in each animal, an infusion of fentanyl was begun. Group 1 received continuous successive infusion rates of 0.05, 0.1, and 0.2 micrograms . kg-1 . min-1 with respective loading doses (given over 20 min) of 15, 15, and 30 micrograms/kg; Group 2 received infusions of 0.2, 0.8, and 3.2 micrograms . kg-1 . min-1 with loading doses of 30, 90, and 270 micrograms/kg, respectively. Group 3 was studied in the same manner except that fentanyl was omitted from the infusion solution. Enflurane MAC was determined at each infusion level and blood samples were analyzed for the concentration of fentanyl. Fentanyl concentrations in plasma were proportional to the infusion rate. Enflurane MAC was decreased significantly in proportion to fentanyl plasma concentrations up to 30 ng/ml where a reduction of MAC by 65% was evident. A threefold higher concentration produced a minimal further reduction. In Group 3 dogs, no change in enflurane MAC was seen. It was concluded that predictable, stable levels of fentanyl in plasma can be achieved, that there is a close relationship between the concentration of fentanyl in plasma and its enflurane sparing effect, and that there is a ceiling to this concentration-response relationship.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7149305     DOI: 10.1097/00000542-198212000-00009

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  15 in total

Review 1.  Partial intravenous anesthesia in cats and dogs.

Authors:  Tanya Duke
Journal:  Can Vet J       Date:  2013-03       Impact factor: 1.008

2.  Cardiorespiratory effects of a 5HT2 antagonist (R51703) in awake and anesthetized dogs.

Authors:  T J Doherty; W N McDonell; D H Dyson; W D Black
Journal:  Can J Vet Res       Date:  1996-07       Impact factor: 1.310

Review 3.  Safety considerations in the use of drug combinations during general anaesthesia.

Authors:  E S Ransom; R A Mueller
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

4.  The interaction of nitrous oxide and fentanyl on the minimum alveolar concentration of sevoflurane blocking motor movement (MACNM) in dogs.

Authors:  Reza Seddighi; Thomas J Doherty; Butch Kukanich; Christine M Egger; Melissa A Henn; Whitney M Long; Barton W Rohrbach
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

5.  Abstracts: annual meeting of the Canadian Anesthetists' Society. June 26-29, 1988, Halifax, Nova Scotia.

Authors: 
Journal:  Can J Anaesth       Date:  1988-05       Impact factor: 5.063

Review 6.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

7.  The cardiovascular sparing effect of fentanyl and atropine, administered to enflurane anesthetized dogs.

Authors:  J E Ilkiw; P J Pascoe; S C Haskins; J D Patz; R Jaffe
Journal:  Can J Vet Res       Date:  1994-10       Impact factor: 1.310

8.  Hormonal and haemodynamic responses to upper abdominal surgery during isoflurane and balanced anaesthesia.

Authors:  S Gelman; J E Rivas; H Erdemir; S Oparil; J Proctor; T MacKrell; L Smith
Journal:  Can Anaesth Soc J       Date:  1984-09

Review 9.  Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J J O'Brien; P Benfield
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 10.  Drug interactions of clinical significance with opioid analgesics.

Authors:  P M Maurer; R R Bartkowski
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.